GLN
GLUTAMINE
Created: | 1999-07-08 |
Last modified: | 2024-09-27 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 20 |
Chiral Atom Count | 1 |
Bond Count | 19 |
Aromatic Bond Count | 0 |
Chemical Component Summary | |
---|---|
Name | GLUTAMINE |
Systematic Name (OpenEye OEToolkits) | (2S)-2,5-diamino-5-oxo-pentanoic acid |
Formula | C5 H10 N2 O3 |
Molecular Weight | 146.144 |
Type | L-PEPTIDE LINKING |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 10.04 | O=C(N)CCC(N)C(=O)O |
SMILES | CACTVS | 3.341 | N[CH](CCC(N)=O)C(O)=O |
SMILES | OpenEye OEToolkits | 1.5.0 | C(CC(=O)N)C(C(=O)O)N |
Canonical SMILES | CACTVS | 3.341 | N[C@@H](CCC(N)=O)C(O)=O |
Canonical SMILES | OpenEye OEToolkits | 1.5.0 | C(CC(=O)N)[C@@H](C(=O)O)N |
InChI | InChI | 1.03 | InChI=1S/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)/t3-/m0/s1 |
InChIKey | InChI | 1.03 | ZDXPYRJPNDTMRX-VKHMYHEASA-N |
Drug Info: DrugBank
DrugBank ID | DB00130 |
---|---|
Name | L-Glutamine |
Groups |
|
Description | A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from glutamic acid and ammonia. It is the principal carrier of nitrogen in the body and is an important energy source for many cells. An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical. |
Synonyms |
|
Brand Names |
|
Indication | Used for nutritional supplementation, also for treating dietary shortage or imbalance. Used to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older [FDA Label]. |
Categories |
|
ATC-Code | A16AA03 |
CAS number | 56-85-9 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
CTP synthase 1 | MKYILVTGGVISGIGKGIIASSVGTILKSCGLHVTSIKIDPYINIDAGTF... | unknown | antagonist,substrate |
Amidophosphoribosyltransferase | MELEELGIREECGVFGCIASGEWPTQLDVPHVITLGLVGLQHRGQESAGI... | unknown | substrate |
Glutamine synthetase | MTTSASSHLNKGIKQVYMSLPQGEKVQAMYIWIDGTGEGLRCKTRTLDSE... | unknown | product of |
Coagulation factor XIII A chain | MSETSRTAFGGRRAVPPNNSNAAEDDLPTVELQGVVPRGVNLQEFLNVTS... | unknown | substrate |
Glutaminase kidney isoform, mitochondrial | MMRLRGSGMLRDLLLRSPAGVSATLRRAQPLVTLCRRPRGGGRPAAGPAA... | unknown | substrate |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
PubChem | 5961, 6992086 |
ChEMBL | CHEMBL930 |
ChEBI | CHEBI:18050, CHEBI:58359 |
CCDC/CSD | LARBAK, LAQZUB |